#United States #XPOVIO #Newton #Karyopharm Therapeutics #NEXPOVIO

Karyopharm Therapeutics Announces Stock Grants

Karyopharm Therapeutics Inc., listed on Nasdaq under the ticker KPTI, is proud to announce a significant step in its commitment to attract and retain top talent in the pharmaceutical industry. In a recent disclosure, the Newton, Massachusetts-based company revealed that it has granted a total of 1,533 restricted stock units (RSUs) to two newly hired employees. This initiative aligns with Karyopharm's strategy to utilize its 2022 Inducement Stock Incentive Plan to not only comply with Nasdaq Listing Rule 5635(c)(4) but also to underscore its dedication to the advancement of innovative cancer therapies.

Details of the Inducement Grants

The RSU awards were allocated effective as of December 31, 2025, marking an important date for the company as it aims to bolster its team involved in developing groundbreaking cancer treatments. Under the awarded RSUs, the new hires will see their shares vest over the subsequent three years, with one-third becoming available on the anniversary of their grant each year. However, it is noteworthy that the vesting of these grants is contingent upon the employees continuing their roles at Karyopharm through the respective vesting dates.

This strategic move is not only a reflection of Karyopharm's focus on cultivating a talented workforce but also signals to the industry the potential of the company in the competitive pharmaceutical field dedicated to oncology. By incentivizing new employees with RSUs, Karyopharm reaffirms its belief in the extraordinary strength of cancer patients and aligns its business practices with its overall mission to deliver innovative therapies that address unmet medical needs.

About Karyopharm Therapeutics

Karyopharm Therapeutics is a pioneering pharmaceutical company renowned for its efforts in developing novel cancer therapies. The firm has positioned itself as a leader in oral compounds that target nuclear export dysregulation, which is a crucial mechanism involved in oncogenesis. Their flagship product, XPOVIO® (selinexor), is the first-in-class oral exportin 1 (XPO1) inhibitor that has gained approval for use in the United States across three oncology indications. The success of XPOVIO has extended beyond the U.S., with regulatory approvals in approximately 50 territories and countries, including significant markets such as the European Union, the United Kingdom—where it is marketed as NEXPOVIO®—and China.

Furthermore, Karyopharm maintains a focused pipeline aimed at various high-unmet-need cancers, including Multiple Myeloma, Endometrial Cancer, and Diffuse Large B-cell Lymphoma (DLBCL), emphasizing its role in transforming cancer treatment paradigms.

To learn more about Karyopharm’s groundbreaking efforts, their scientific innovations, and the people behind the mission, visit their website at www.karyopharm.com and check out their updates on social media via LinkedIn and X at @Karyopharm.

Conclusion

The recent grant of RSUs to new employees is just one of the many steps that Karyopharm Therapeutics is taking to strengthen its workforce and enhance its innovative capabilities in the oncology sector. As they continue their journey in transforming cancer care, these strategic ingredients will help propel their mission forward in the ever-evolving landscape of pharmaceutical development.